TITLE

Xenical account moves to Y&R

PUB. DATE
August 2000
SOURCE
Medical Marketing & Media;Aug2000, Vol. 35 Issue 8, p24
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Hoffmann-La Roche has moved its account for Xenical to Y&R Advertising. Previous handling of the account by Lowe Consumer Healthcare; Awarding of the first professional promotion for Xenical to Sudler and Hennessey.
ACCESSION #
3557728

 

Related Articles

  • FIRST CANADIAN TRIAL FOR XENICAL LAUNCHED.  // Worldwide Biotech;Mar2001, Vol. 13 Issue 3, p5 

    Reports that Hoffman-La Roche Limited has initiated a clinical trial to evaluate its weight loss medication Xenical in Canada.

  • Orlistat approved.  // Healthy Weight Journal;Sep/Oct1999, Vol. 13 Issue 5, p66 

    Reports on the approval of the drug orlistat from Roche Laboratories for the treatment of obesity. Efficacy of the drug; Side effects of the drug.

  • Obesity drugs trim ads. Goetzl, David // Advertising Age;8/13/2001, Vol. 72 Issue 33, p10 

    The article reports on the decision of obesity drug manufacturers Hoffmann-La Roche and Abbott Pharmaceuticals to discontinue direct-to-consumer (DTC) advertising for their products. Hoffmann-La Roche's new campaign, launched in February 2001, which was designed in part to divert attention from...

  • WOLFE: STRICTER CONTROL OF DTC NEEDED. Dickinson, James G. // Medical Marketing & Media;Apr2002, Vol. 37 Issue 4, p34 

    Reports developments related to direct-to-consumer advertising of drugs in the U.S. as of April 2002. Increase in the direct-to-consumer promotions; Failure of Hoffmann-LaRoche Inc. to include statements of side effects on the Xeloda advertisement; Preference of drug companies to use network...

  • Honesty is the Best Policy. Hallahan, Mary; Mordock, Jeff // Pharmaceutical Executive;Nov99, Vol. 19 Issue 11, p87 

    Provides information on the direct-to-consumer advertising for Hoffmann-La Roche's diet drug, Xenical. Budget for the campaign; Analysis of Xenical advertisements; Goal of the campaign.

  • Roche Looks for New Spin on Xenical.  // Pharmaceutical Executive;May2000, Vol. 20 Issue 5, p154 

    Announces the search of Hoffman-La Roche for an advertising agency to promote its antiobesity drug Xenical. Revenues generated by sales of the drug for the first quarter of 2000; Advertising expenditures of the company for the drug; Media buys that the company initiated.

  • Xenical ads lack balance.  // Healthy Weight Journal;May/Jun2000, Vol. 14 Issue 3, p35 

    Deals with the letter made by the United States Food and Drug Administration (FDA) to Hoffman-LaRoche Inc. on the television advertisement of its Xenical or orlistat drug. FDA complaint on the advertisement's imbalances; Action taken by the company on the complaint.

  • Roche sheds Lowe as Xenical agency. Goetzl, David; Snyder Bulik, Beth // Advertising Age;4/17/2000, Vol. 71 Issue 17, p1 

    This article reports on the decision of Hoffman-La Roche to replace the Lowe Group as the advertising agency for weight loss drug Xenical in April 2000. The account for Xenical includes an estimated $80 million direct-to-consumer business as well as physician-targeted advertising. One hurdle...

  • Roche Kicks Off Review for Xenical Fat Drug. McMains, Andrew // Adweek Eastern Edition;4/17/2000, Vol. 41 Issue 16, p4 

    Reports on Roche Laboratories has launched a review of the Xenical account at Lowe Consumer Healthcare. Creative and media duties in play; Potential side effects of Xenical.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics